Novo Nordisk’s Q3 2025 sales outperformed market expectations, marking a positive start for new CEO Mike Doustdar. Despite ongoing challenges in the U.S. obesity segment and intense competition, the company’s strong performance reflects effective commercial execution and optimism for renewed growth under fresh leadership.
Novo Nordisk delivered encouraging Q3 sales results in 2025, exceeding analyst forecasts during the first financial report under CEO Maziar Mike Doustdar. Taking office in August, Doustdar faces significant pressures amid declining market share and legal battles but began his tenure with a notable sales uplift that investors welcomed.
Key highlights include:
Q3 sales surpassed expectations, signaling resilience despite a highly competitive U.S. obesity market where Novo faces stiff competition from Eli Lilly.
The company continues to focus on its flagship semaglutide-based drugs, including Wegovy and Ozempic, which drive a significant portion of revenue.
New CEO Doustdar is steering a strategic turnaround, addressing commercial execution and cost efficiencies after multiple guidance cuts earlier in 2025.
While profit pressure and ongoing restructuring remain challenges, sales growth exceeded estimates, providing a cautious boost to investor confidence.
This quarter also coincides with an ongoing acquisitive battle with Pfizer over Metsera, underscoring the high stakes in next-generation obesity treatments.
Despite a tough year with shares down over 50%, Novo Nordisk’s Q3 results provide a glimmer of hope for recovery and renewed strategic clarity under new leadership.
Sources: Reuters, Bloomberg, TradingKey, Novo Nordisk official releases